相关实验视频

Updated: May 27, 2025

A Novel High-resolution In vivo Imaging Technique to Study the Dynamic Response of Intracranial Structures to Tumor Growth and Therapeutics

A Novel High-resolution In vivo Imaging Technique to Study the Dynamic Response of Intracranial Structures to Tumor Growth and Therapeutics

Published on: June 16, 2013

关于免疫血管微环境中免疫治疗结果的HIF-1a的研究进展

Shaoyan Shi¹, Xuehai Ou¹, Chao Liu¹

¹Department of Hand Surgery, Honghui Hospital, Xi'an Jiaotong University, Xi'an, China.

Frontiers in immunology

|February 21, 2025

概括

缺氧诱导因子-1α (HIF-1α) 通过改变瘤微环境,促进瘤生长和抵抗免疫治疗. 针对HIF-1α提供了一个有希望的策略,以提高癌症治疗效率.

科学领域:

在瘤学瘤学.
免疫学免疫学免疫学
分子生物学分子生物学

背景情况:

低氧诱导因子-1α (HIF-1α) 是细胞适应低氧条件的关键调节者.
由HIF-1α驱动的瘤缺氧显著影响免疫血管微环境 (IVM).
HIF-1α影响瘤进展,血管生成,免疫抑制和细胞外基质重塑.

研究的目的:

在IVM中探索HIF-1α的分子机制.
了解HIF-1α在促进抗癌免疫疗法的作用.
审查针对HIF-1α的潜在治疗策略,以提高免疫治疗结果.

主要方法:

关于HIF-1α,瘤缺氧和免疫治疗的现有文献的综述.
分析瘤微环境中由HIF-1α调节的分子通路.
检查针对HIF-1α的治疗干预措施.

主要成果:

HIF-1α介导的缺氧驱动血管生成和免疫抑制.
HIF-1α提高免疫检查点的调节,并促进免疫抑制细胞的招募.
这些影响导致免疫疗法 (如检查点抑制剂) 的疗效降低.
通过抑制剂,基因编辑或缺氧调节准HIF-1α显示出有希望.

结论:

HIF-1α在建立免疫抑制性瘤微环境方面发挥着关键作用,阻碍了免疫治疗.
旨在抑制HIF-1α或调节缺氧的策略是克服免疫疗法耐药性的潜在方法.
需要进一步的研究来开发在癌症治疗中针对缺氧驱动的免疫抑制的创新干预措施.

关键词:

在 HIF-1 α α 中.在VEGF中,VEGF是VEGF.免疫血管微型环境免疫血管微环境和免疫疗法免疫疗法耐药性免疫疗法耐药性机器学习 HIF-1a 机器学习个性化癌症治疗个性化癌症治疗

更多相关视频

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Published on: February 24, 2023

Intravital Microscopy of Monocyte Homing and Tumor-Related Angiogenesis in a Murine Model of Peripheral Arterial Disease

Intravital Microscopy of Monocyte Homing and Tumor-Related Angiogenesis in a Murine Model of Peripheral Arterial Disease

Published on: August 26, 2017

相关概念视频

Regulation of Angiogenesis and Blood Supply

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits. Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...

Mechanism of Angiogenesis

Mechanism of Angiogenesis

Blood vessel formation starts early during embryonic development, around day 7. In the extraembryonic yolk sac, mesodermal precursor cells called hemangioblast proliferate and differentiate into angioblast. Angioblasts express vascular endothelial growth factor receptor 2 or VEGFR2, which binds VEGF-A, a proangiogenic factor, guiding blood vessel formation. VEGF signaling promotes angioblasts to form a blood island in the developing embryo. Angioblasts further differentiate, giving rise to...

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Cancer Therapies

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...